{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Dietary Supplement Label Database|Enzyme" in comments (approximate match)
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
(2023)
Source URL:
First approved in 2023
Source:
Quit Smoking Patch by Guangzhou Hanhai Trading Co., Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2023
Source:
ProBionexxProbiotic Support by SKYA HEALTH, LLC
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Dechangling by Shenzhen Deyintang Biotechnology Co., Ltd.
(2022)
Source URL:
First approved in 2022
Source:
Dechangling by Shenzhen Deyintang Biotechnology Co., Ltd.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02913170: Phase 4 Interventional Completed Hypercholesterolemia
(2015)
Source URL:
First approved in 2021
Source:
Vigen Dr. Nattokinase by Vigen medical
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2019
Source:
Stozyme by Chunwoo Pharmaceutical Co., Ltd.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01715493: Phase 4 Interventional Completed Chronic Obstructive Pulmonary Disease
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 1995
Source:
21 CFR 341
Source URL:
Class:
PROTEIN
Status:
Other
Class:
STRUCTURALLY DIVERSE
